ACER News and Press, Acer Therapeutics Inc. From 06/10/21

Following a recent Type B meeting with the FDA, Acer Therapeutics (ACER), plans to conduct clinical trial of Edsivo (celiprolol) in patients with COL3A1+ vascular Ehlers-Danlos Syndrome (vEDS).EDS is an inherited disorder that affects the connective tissues in the body - p...

Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled FDA indicates agreement with submission of proposed protocol under a Special Protocol Assessment (SPA) with possible breakt...

Acer Therapeutics (ACER) said that it plans to submit an NDA for its Urea Cycle Disorders ((UCDs)) treatment ACER-001 to the U.S. FDA in the third-quarter of this year, following a pre-NDA meeting with the health regulator.ACER-001 is a proprietary immediate release powder...

NEWTON, Mass. and GENEVA, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with signif...

Acer Therapeutics (ACER): Q1 GAAP EPS of -$0.11 beats by $0.30.Revenue of $3.99M beats by $3.49M.Press Release For further details see: Acer Therapeutics EPS beats by $0.30, beats on revenue

NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported fina...

NEWTON, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...

NEWTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS NOTICE TO CURRENT ACER THERAPEUTICS INC. STOCKHOLDERS PLEASE TAKE NOTICE that this acti...

Some Of The Best Penny Stocks To Watch Early This Week This week has started stronger than the last & we have plenty of trending penny stocks to watch as a result. Last week the markets sold off, with tech continuing its move lower. What’s more, over the weekend, new virus da...

RELIEF THERAPEUTICS Holding (RLFTF) and Acer Therapeutics (ACER) have entered into a Collaboration and License Agreement (“CLA”) for worldwide development and commercialization of ACER-001, a proprietary powder formulation of sodium phenylbutyrate ((NaPB)) designed to be both ta...